Viatris Inc (VTRS) Profitability Comparisons, Net Margin, Gross Margin, Tax rate, Cash Flow Margin Comparisons - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Viatris Inc   (NASDAQ: VTRS)

Viatris Inc Profitability Comparisons

Select each Category to receive further Information



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VTRS Profitability Ratio

 Company Industry Sector S&P 500
Gross Profit Margin (Q2 MRQ) 38.77 % 70.91 % 65.43 % 46.06 %
Gross Margin (Q2 TTM) 34.83 % 71.73 % 66.39 % 46.3 %
Gross Profit Margin 5 Yr. Avg. 37.21 % 66.05 % 64.67 % 47.07 %
EBITDA Margin (Q2 MRQ) 47.17 % 22.25 % 19.59 % 20.57 %
EBITDA Margin (Q2 TTM) 24.87 % 25.28 % 20.86 % 19.07 %
EBITDA Margin 5 Yr. Avg. 20.75 % 45.98 % 31.16 % 22.06 %
Operating Margin (Q2 MRQ) 0.17 % 17.27 % 16.57 % 16.03 %
Operating Margin (Q2 TTM) -0.59 % 20.33 % 17.92 % 16.33 %
Operating Margin 5 Yr. Avg. --0.77 % 15.55 % 14.41 % 17.09 %
Pre-Tax Profit Margin (Q2 MRQ) -1.7 % 13.66 % 10.93 % 13.94 %
Pre-Tax Profit Margin (Q2 TTM) -4.49 % 16.7 % 12.86 % 13.09 %
Pre-Tax Profit Margin 5 Yr. Avg. - 13.09 % 10.45 % 12.49 %
Net Margin (Q2 MRQ) -3.16 % 10.09 % 8.14 % 11.41 %
Net Margin (Q2 TTM) -2.79 % 13.13 % 9.99 % 10.76 %
Net Margin 5 Yr. Avg. - 6.22 % 6.23 % 9.95 %



Business Segment Profit Margin
 
Brands
  Explore Brands Segment  -
Generics
  Explore Generics Segment  -
Zoloft
  Explore Zoloft Segment  -
Xalabrands
  Explore Xalabrands Segment  -
Greater China
  Explore Greater China Segment  72.23 %
Developed Markets
  Explore Developed Markets Segment  40.63 %
Japan, Australia and New Zealand
  Explore Japan, Australia and New Zealand Segment  24.75 %
Emerging Markets
  Explore Emerging Markets Segment  44.3 %
Lipitor ®
  Explore Lipitor ® Segment  -
Norvasc ®
  Explore Norvasc ® Segment  -
EpiPen® Auto-Injectors
  Explore EpiPen® Auto-Injectors Segment  -
Lyrica ®
  Explore Lyrica ® Segment  -
Viagra ®
  Explore Viagra ® Segment  -
Creon ®
  Explore Creon ® Segment  -
Celebrex ®
  Explore Celebrex ® Segment  -
Zoloft ®
  Explore Zoloft ® Segment  -
Effexor ®
  Explore Effexor ® Segment  -
Yupelri ®
  Explore Yupelri ® Segment  -
Dymista ®
  Explore Dymista ® Segment  -
 

Company's Cashflow Profitability & Other



Profitability Ratios Company Industry Sector S&P 500
Free Cash Flow Margin (Q2 MRQ) 8.76 % -0.01 % 0.21 % 1.39 %
Free Cash Flow Margin (Q2 TTM) 13.26 % 17.24 % 13.98 % 9.19 %
Free Cash Flow Margin 5 Yr. Avg. - 20.2 % 15.38 % 14.52 %
Net Cash Flow Margin (Q2 MRQ) 0 % 0.02 % -0.02 % 0.13 %
Net Cash Flow Margin (Q2 TTM) 8.4 % -0.78 % 0.08 % 1.81 %
Net Cash Flow Margin 5 Yr. Avg. - 4.28 % 3.13 % 5.85 %
Effective Tax Rate (Q2 MRQ) -85.63 % 25.98 % 25.41 % 18.83 %
Effective Tax Rate (Q2 TTM) 37.98 % 21.22 % 22.81 % 19.33 %
Effective Tax Rate 5 Yr. Avg. - 15.14 % 20.39 % 19.86 %
Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.